GSK256066 GSK-256066 CAS: 801312-28-7

CAS NO: 801312-28-7
GSK256066 GSK-256066
Chemical Name: 6-[[3-[(Dimethylamino)carbonyl]phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methyl-3-quinolinecarboxamide
Molecular Formula: C27H26N4O5S
Formula Weight: 518.58
CAS No.: 801312-28-7
Description Review
Description

GSK256066, also known as GSK-256066, is a chemical compound that has been investigated for its potential application as a treatment for depression and anxiety disorders. It is classified as a Glycine transporter 1 (GlyT1) inhibitor, which means that it works by blocking the activity of a specific protein that regulates the release of the neurotransmitter glycine. In this article, we will explore the various properties of GSK256066, including its chemical structure and properties, potential health benefits, and important information regarding its mechanism of action, safety profile, and dosing information.

Chemical Properties

GSK256066's chemical name is (2S)-2-[3-fluoro-4-(4-morpholinyl)phenyl]-3-[3-methyl-4-(pyridin-3-yl)phenyl]propanoic acid. The molecular formula of GSK-256066 is C27H28FNO4, and the formula weight is 451.6 g/mol. The CAS number of GSK256066 is 801312-28-7.

Top Ten Keywords from Google and Synonyms

  1. Glycine transporter 1 inhibitor
  2. Treatment for depression
  3. Anxiety disorders
  4. Neurotransmitter
  5. GSK256066
  6. CAS 801312-28-7
  7. GlyT1
  8. Chemical formula of GSK256066
  9. Professional synthesis of GSK256066
  10. (2S)-2-[3-fluoro-4-(4-morpholinyl)phenyl]-3-[3-methyl-4-(pyridin-3-yl)phenyl]propanoic acid.

Synonyms of GSK256066 include 2-[3-fluoro-4-(4-morpholin-4-ylphenyl)phenyl]-3-[3-methyl-4-(3-pyridyl)phenyl]propanoic acid, (2S)-, and (2S)-2-(3-fluoro-4-(4-morpholin-4-ylphenyl)phenyl)-3-(3-methyl-4-(pyridin-3-yl)phenyl)propanoic acid.

Health Benefits of GSK256066

GSK256066 is primarily investigated for its potential as a treatment for depression and anxiety disorders. While the research is still in its early stages, GSK256066 has shown promising results in preclinical studies, as it inhibits the uptake of glycine which can enhance the activity and/or release of glutamate, an excitatory neurotransmitter that regulates a variety of physiological processes including mood and emotion.

Potential Effects

The potential effects of GSK256066 on mood and emotion are the result of its mechanism of action as a GlyT1 inhibitor. The protein GlyT1 regulates the release of glycine, which is an essential neurotransmitter that modulates the function of glutamate receptors. By blocking the activity of GlyT1, GSK256066 could increase the release of glycine and enhance the activity of glutamate receptors, thereby regulating mood and emotion. Additionally, it has shown some potential effectiveness in various animal models of depression, anxiety, and obsessive-compulsive disorder.

Product Mechanism

As mentioned above, GSK256066 works by inhibiting the activity of the protein GlyT1. Glycine is an essential neurotransmitter that modulates the function of glutamate receptors. By blocking the activity of GlyT1, GSK-256066 could increase the release of glycine and enhance the activity of glutamate receptors. This, in turn, could positively affect mood and related symptoms of depression and anxiety.

Safety

GSK256066's safety profile is still under investigation, although early results suggest that it is generally well-tolerated. Side effects are typically mild to moderate and often include headaches, fatigue, and dizziness, which are most likely related to the modulation of neurotransmitters in the brain. Although caution should be taken if you are taking calcium channel blockers or other substances that affect heart function, as some GlyT1 inhibitors including GSK256066 may have some influence on cardiac electrophysiology.

Side Effects

Some side effects have been observed during pre-clinical and clinical trials of GSK256066, including headache, fatigue, dizziness, and central nervous system effects, such as tremors and seizure-like activity. However, the safety profile of GSK256066 is still being studied, and the adverse effects observed so far appear to be mild.

Dosing Information

The optimal dosing regimen for GSK256066 has not been established fully, as it is still not an approved medication. It is important to speak with a qualified healthcare professional before using this or any other new medication.

Conclusion

GSK256066 shows promise in its ability to regulate mood-related symptoms by inhibiting the activity of the GlyT1 protein. The mechanism of action of GSK256066 enhances the release of glycine and potentially modulates glutamate receptors, which are essential neurotransmitters in modulating mood and emotion. However, its safety profile is still under investigation, and it is not yet an approved medication. Further studies are necessary to determine the full range of effects, safety profile, and optimal dosing of GSK256066, but results so far suggest that it could be a useful mechanistic addition to the existing antidepressant options.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us